- Trials with a EudraCT protocol (925)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
925 result(s) found for: Cell Growth.
Displaying page 1 of 47.
EudraCT Number: 2007-001364-72 | Sponsor Protocol Number: EP00-402 | Start Date*: 2008-01-04 | |||||||||||
Sponsor Name:Sandoz GmbH | |||||||||||||
Full Title: Long-term safety follow-up after growth hormone treatment (rhGH) of short children born Small for Gestational Age (SGA) | |||||||||||||
Medical condition: Growth disturbance (current height standard deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children born small for gestational age (SGA), with a birth weight and/or length be... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) DE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018614-70 | Sponsor Protocol Number: D791AC00014 | Start Date*: 2010-09-03 | |||||||||||||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||
Full Title: An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Gr... | |||||||||||||||||||||||
Medical condition: Non Small Cell Lung Cancer. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PT (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) NO (Completed) HU (Completed) GR (Completed) BG (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023869-21 | Sponsor Protocol Number: ML25575 | Start Date*: 2011-02-09 | ||||||||||||||||
Sponsor Name:Roche Oy | ||||||||||||||||||
Full Title: A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal ... | ||||||||||||||||||
Medical condition: Locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004324-11 | Sponsor Protocol Number: NVALT-15 | Start Date*: 2014-06-02 | ||||||||||||||||
Sponsor Name:Stichting NVALT studies | ||||||||||||||||||
Full Title: Phase II study with oral fibroblast growth factor-1 inhibitor BIBF1120 as second line treatment in lung carcinoma patients harboring fibroblast growth factor receptor-1 gene amplification (NVALT-15... | ||||||||||||||||||
Medical condition: Non small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003657-26 | Sponsor Protocol Number: ARD10248 | Start Date*: 2012-01-16 | |||||||||||
Sponsor Name:sanofi aventis recherche et développement | |||||||||||||
Full Title: An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refrac... | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002506-58 | Sponsor Protocol Number: EP00-401 | Start Date*: 2007-08-14 | |||||||||||
Sponsor Name:Sandoz GmbH | |||||||||||||
Full Title: Long-term phase IV multicentre study on the safety and efficacy of Omnitrope® (rhGH) in short children born Small for Gestational Age (SGA) | |||||||||||||
Medical condition: Growth disturbance (current height standard deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children born small for gestational age (SGA), with a birth weight and/or length be... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010288-17 | Sponsor Protocol Number: 1516 | Start Date*: 2009-07-13 |
Sponsor Name:Karolinska Hospital | ||
Full Title: Breast cell turnover and mammographic density in women with Polycystic Ovary Syndrome (PCOS) | ||
Medical condition: Polycystic ovary syndrome (PCOS) is the most common hormonal aberration in women of fertile age, with a prevalence of 5-10%, and is associated with chronic anovulation, hyperandrogenism and PCO mo... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002168-26 | Sponsor Protocol Number: ML27880 | Start Date*: 2012-01-05 | ||||||||||||||||
Sponsor Name:Roche (Magyarország) Kft. | ||||||||||||||||||
Full Title: OPEN LABEL STUDY OF ERLOTINIB (TARCEVA®) AS SINGLE AGENT FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LUNG ADENOCARCINOMA WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (E... | ||||||||||||||||||
Medical condition: Open label study of erlotinib (Tarceva®) as single agent first line treatment of patients with locally advanced or metastatic lung adenocarcinoma with activating Epidermal Growth Factor Receptor (E... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) LV (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001413-34 | Sponsor Protocol Number: VIHCREC01 | Start Date*: 2005-04-21 |
Sponsor Name:Bonaventura Clotet Sala | ||
Full Title: ESTUDIO DE UNA DOBLE ESTRATEGIA PARA INDUCIR Y EXPANDIR EL REPERTORIO DE CÉLULAS T BASADA EN LA ADMINISTRACIÓN DE HORMONA DE CRECIMIENTO Y VACUNA EN PACIENTES CON INFECCIÓN POR EL VIH 1 | ||
Medical condition: HIV-1 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003361-18 | Sponsor Protocol Number: PM0259CA229J1 | Start Date*: 2013-01-24 | |||||||||||||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||||||||||||
Full Title: Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after a failure to tr... | |||||||||||||||||||||||
Medical condition: Patients with: -Histologically or cytologically confirmed NSCLC (stage IIIB or IV) and -epidermal growth factor receptor (EGFR) positive mutation and -previously treated with tyrosine kinase inhibi... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000307-10 | Sponsor Protocol Number: TREM | Start Date*: 2015-05-27 |
Sponsor Name:Oslo university hospital | ||
Full Title: AZD9291, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies. | ||
Medical condition: Locally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) DK (Completed) FI (Ongoing) LT (Ongoing) SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000781-23 | Sponsor Protocol Number: GEN207 | Start Date*: 2008-06-09 | ||||||||||||||||
Sponsor Name:Genmab A/S | ||||||||||||||||||
Full Title: An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination wi... | ||||||||||||||||||
Medical condition: Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000796-14 | Sponsor Protocol Number: HM10/9652 | Start Date*: 2011-12-01 | |||||||||||
Sponsor Name:Leeds Teaching Hospitals NHS Trust | |||||||||||||
Full Title: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL | |||||||||||||
Medical condition: Chronic Lymphocytic Leukaemia (CLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000104-42 | Sponsor Protocol Number: U31287-A-U201E | Start Date*: 2013-06-14 | |||||||||||||||||||||
Sponsor Name:DAIICHI SANKYO DEVELOPMENT LTD. | |||||||||||||||||||||||
Full Title: Open-label, Non-randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) - Extension | |||||||||||||||||||||||
Medical condition: Treatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001642-28 | Sponsor Protocol Number: INCB39110-205 | Start Date*: 2015-09-28 | |||||||||||||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||||||||||||
Full Title: A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer Whose Tu... | |||||||||||||||||||||||
Medical condition: Male or female individuals, aged 18 years or older who have Stage IIIB/IV or recurrent NSCLC. Subjects must have tumors that are positive for EGFR-activating mutation, namely, exon 19 deletions, e... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005098-35 | Sponsor Protocol Number: ETOP7-14NICHE | Start Date*: 2015-05-18 | |||||||||||
Sponsor Name:ETOP (European Thoracic Oncology Platform) | |||||||||||||
Full Title: Afatinib in pretreated patients with advanced NSCLC harbouring HER2 exon 20 mutations | |||||||||||||
Medical condition: Advanced stage NSCLC, harbouring HER2 exon 20 mutations | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002997-31 | Sponsor Protocol Number: SCH/05/015 | Start Date*: 2006-08-10 |
Sponsor Name:Sheffield Children's NHS Trust | ||
Full Title: A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis. | ||
Medical condition: Individuals with cystic fibrosis develop diabetes. They exhibit abnormal glucose handling (impaired glucose tolerance), poor growth and a decline in lung function before overt diabetes develops. E... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006229-23 | Sponsor Protocol Number: PTCLS-IDE | Start Date*: 2022-04-07 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas. | |||||||||||||
Medical condition: peripheral T Cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002161-30 | Sponsor Protocol Number: 1302.5 | Start Date*: 2015-09-07 | |||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim International GmbH | |||||||||||||||||||||||
Full Title: A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Sm... | |||||||||||||||||||||||
Medical condition: Recurrent or metastatic disease (Stage IV), histologically or cytologically confirmed advanced nonsquamous Non-Small Cell Lung Cancer. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) PT (Completed) ES (Completed) DE (Completed) PL (Completed) HR (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000058-89 | Sponsor Protocol Number: D516AC00001 | Start Date*: 2021-01-06 | |||||||||||||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||
Full Title: A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treat... | |||||||||||||||||||||||
Medical condition: Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) BG (Ongoing) PL (Ongoing) IT (Ongoing) FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.